September 2000 – Vol 2 – No. 3

Clinical research

Psychotropic medication, psychiatric disorders, and higher brain functions
Pierre Schulz , MD; Thierry Steimer, PhD

The value of assessing cognitive function in drug development
Keith A. Wesnes, PhD

Early diagnosis of Alzheimer’s disease: update on combining genetic and brain-imaging measures
Gary W. Small, MD

Schizophrenia: vulnerability versus disease.
Ming T. Tsuang, MD, PhD, DSc, FRCPsych; William S. Stone, PhD; Stephen V. Faraone, PhD

A public health approach to clinical therapeutics in psychiatry: directions for new research
Barry D. Lebowitz, PhD

Advances in the endovascular treatment of intracranial arteriovenous malformations
Alain Tournade, MD; Carlos Riquelme, MD

Functional and topographical considerations in the surgical management of cerebral vascular malformations
Gérard Mohr, MD, FRCS(C); Donatella Tampieri, MD, FRCP(C); Denise Klein, PhD; Lahbib Soualmi, PhD

Pharmacological aspects

Designing and interpreting the results of first-time-to-man studies
Alain A. Patat, MD

Pharmacological models in Alzheimer’s disease research
Christian Gilles, MD; Stéphane Ertlé, MS

Treatment mechanisms: traditional and new antipsychotic drugs
Carol A. Tamminga, MD

Basic research

FDA relations during drug development
Jules T. Mitchel, MBA, PhD

NMDA receptor function, memory, and brain aging
John W. Newcomer, MD; Nuri B. Farber, MD; John W. Olney, MD

Inflammation and the pathophysiology of Alzheimer’s disease
M. Murphy Jr. Greer , MD, PhD

Neural models of schizophrenia
Stephan Heckers, MD

Neurotoxicity of NMDA antagonists: a glutamatergic theory of schizophrenia based on selective impairment of local inhibitory feedback circuits
Heinz Grunze, MD; Andreas Bender, MD; Stefan Wendhof, MD; Martin Schäfer, MD; Dan Rujescu, MD

Serotonergic and noradrenergic function in depression: clinical correlates
Fabrice Duval, MD; Marie-Claude Mokrani, PhD; Paul Bailey, MD; Humberto Corrêa, MD; Marc-Antoine Crocq, MD; Thanh Son Diep, MD; Jean-Paul Macher, MD